KR20060033247A - Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor - Google Patents
Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor Download PDFInfo
- Publication number
- KR20060033247A KR20060033247A KR1020040082247A KR20040082247A KR20060033247A KR 20060033247 A KR20060033247 A KR 20060033247A KR 1020040082247 A KR1020040082247 A KR 1020040082247A KR 20040082247 A KR20040082247 A KR 20040082247A KR 20060033247 A KR20060033247 A KR 20060033247A
- Authority
- KR
- South Korea
- Prior art keywords
- magnesium
- group
- composition
- alcohol
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 206010019133 Hangover Diseases 0.000 title claims abstract description 34
- 150000002681 magnesium compounds Chemical class 0.000 title claims abstract description 23
- 159000000003 magnesium salts Chemical class 0.000 title claims abstract description 23
- 239000009724 Salvia extract Substances 0.000 claims abstract description 33
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000011777 magnesium Substances 0.000 claims abstract description 11
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 11
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 26
- 239000000395 magnesium oxide Substances 0.000 claims description 24
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 15
- 239000001755 magnesium gluconate Substances 0.000 claims description 14
- 229960003035 magnesium gluconate Drugs 0.000 claims description 14
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 14
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 13
- 229940091250 magnesium supplement Drugs 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 9
- 229930182817 methionine Natural products 0.000 claims description 9
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 8
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 8
- 229960003767 alanine Drugs 0.000 claims description 8
- 229930003451 Vitamin B1 Natural products 0.000 claims description 7
- 229960004452 methionine Drugs 0.000 claims description 7
- 229960003495 thiamine Drugs 0.000 claims description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 7
- 239000011691 vitamin B1 Substances 0.000 claims description 7
- 235000010374 vitamin B1 Nutrition 0.000 claims description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 240000000530 Alcea rosea Species 0.000 claims description 3
- 235000017334 Alcea rosea Nutrition 0.000 claims description 3
- 235000017303 Althaea rosea Nutrition 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 229960002337 magnesium chloride Drugs 0.000 claims description 3
- 235000011147 magnesium chloride Nutrition 0.000 claims description 3
- 239000004337 magnesium citrate Substances 0.000 claims description 3
- 229960005336 magnesium citrate Drugs 0.000 claims description 3
- 235000002538 magnesium citrate Nutrition 0.000 claims description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 3
- 239000000347 magnesium hydroxide Substances 0.000 claims description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 3
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims description 3
- 239000000626 magnesium lactate Substances 0.000 claims description 3
- 229960004658 magnesium lactate Drugs 0.000 claims description 3
- 235000015229 magnesium lactate Nutrition 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 229940057948 magnesium stearate Drugs 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 229960003390 magnesium sulfate Drugs 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 62
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 17
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 230000035622 drinking Effects 0.000 abstract description 5
- 210000001914 gastric parietal cell Anatomy 0.000 abstract description 4
- 235000017276 Salvia Nutrition 0.000 abstract description 3
- 210000003494 hepatocyte Anatomy 0.000 abstract description 3
- 235000013334 alcoholic beverage Nutrition 0.000 abstract 2
- 241001072909 Salvia Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 12
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 4
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 240000000724 Berberis vulgaris Species 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930194927 Miltionone Natural products 0.000 description 1
- WVVOBOZHTQJXPB-UHFFFAOYSA-N N-anilino-N-nitronitramide Chemical compound [N+](=O)([O-])N(NC1=CC=CC=C1)[N+](=O)[O-] WVVOBOZHTQJXPB-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- HZZOEADXZLYIHG-UHFFFAOYSA-N magnesiomagnesium Chemical compound [Mg][Mg] HZZOEADXZLYIHG-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229930183842 salvianolic acid Natural products 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분과 단삼추출물을 포함하는 숙취의 예방 및 해소용 조성물, 및 기능성 주류에 관한 것이다.The present invention relates to a composition for preventing and eliminating hangovers, and functional liquor comprising one or more components selected from the group consisting of magnesium compounds and magnesium salts and salvia extract.
상기의 숙취의 예방 및 해소용 조성물은 알코올 및 아세트알데히드 대사를 촉진하고 간세포 및 위벽세포를 보호하여, 알코올의 부작용을 최소화시키며, 상기의 기능성 주류는 주류 복용시의 숙취를 최소화 하는 우수한 효과를 제공한다.
The composition for preventing and eliminating hangover promotes alcohol and acetaldehyde metabolism and protects hepatocytes and gastric parietal cells, thereby minimizing side effects of alcohol, and the functional alcoholic beverage provides an excellent effect of minimizing hangover when drinking alcoholic beverages. do.
마그네슘, 단삼, 숙취해소, 알코올, 아세트알데히드Magnesium, Salvia, Hangover, Alcohol, Acetaldehyde
Description
도 1은 산화마그네슘과 단삼을 포함하는 조성물을 알코올에 혼합하여 쥐에게 경구투여 하였을 때 혈중 알코올 농도에 미치는 영향을 다른 투여군과 비교하여나타낸 것이다. Figure 1 shows the effect on the blood alcohol concentration when compared to the other administration group when the composition containing magnesium oxide and dansam mixed with alcohol orally administered to the rat.
도 2는 산화마그네슘과 단삼을 포함하는 조성물을 알코올에 혼합하여 쥐에게 경구투여 하였을 때 시간에 따른 혈중 알코올 농도의 변화를 나타낸 것이다 (M1:산화마그네슘 2 mg/kg + 단삼추출물 2mg/kg; M2: 산화마그네슘 10 mg/kg + 단삼추출물 2mg/kg). Figure 2 shows a change in blood alcohol concentration over time when orally administered to mice mixed with a composition comprising magnesium oxide and dansam (M1:
도 3은 산화마그네슘과 단삼을 포함하는 조성물을 알코올에 혼합하여 쥐에게 경구투여 하였을 때 시간에 따른 혈중 아세트알데히드 농도의 변화를 나타낸 것이다(M1:산화마그네슘 2 mg/kg + 단삼추출물 2 mg/kg; M2: 산화마그네슘 10 mg/kg + 단삼추출물 2 mg/kg). Figure 3 shows the change in acetaldehyde concentration of blood with time when orally administered to mice mixed with a composition containing magnesium oxide and salvia (M1:
도 4는 글루콘산 마그네슘과 단삼을 포함하는 조성물을 알코올에 혼합하여 쥐에게 경구투여 하였을 때 시간에 따른 혈중 알코올 농도의 변화를 나타낸 것이다(M: 글루콘산 마그네슘 10 mg/kg + 단삼추출물 2 mg/kg).
Figure 4 shows a change in the blood alcohol concentration with time when orally administered to mice mixed with a composition containing magnesium gluconate and salvia (M:
본 발명은 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분과 단삼추출물을 포함하는 숙취의 예방 및 해소용 조성물, 및 기능성 주류에 관한 것이다.
The present invention relates to a composition for preventing and eliminating hangovers, and functional liquor comprising one or more components selected from the group consisting of magnesium compounds and magnesium salts and salvia extract.
술은 인류가 오랫동안 이용해 온 것으로 인간 관계 도모, 스트레스 해소, 수면촉진, 신진 대사촉진 등 유효한 면이 있는 반면 과음을 계속하는 경우에는 간에 치명적인 질병을 유발시키고, 과다한 알코올은 체내에서 흡수 및 분해가 잘 이루어지지 않아 두통과 속쓰림을 가져온다. Alcohol has been used for a long time by humans, and it is effective in promoting relationships, relieving stress, promoting sleep, and promoting metabolism, but if excessive drinking continues, it causes fatal diseases in the liver, and excessive alcohol is easily absorbed and broken down by the body. It doesn't work, leading to headaches and heartburn.
술의 주성분은 에탄올인데 섭취하면 주로 간에서 알코올디히드로게나제(alcohol dehydrogenase)에 의해 대사되어 아세트알데히드로 전환되며, 더 대사가 진행되면 아세트알데히드디히드로게나제(acetaldehyde dehydrogenase)에 의해 탄산가스와 물로 분해된다. 보통 적당량의 음주시에는 이들 효소가 원활하게 작용하여 부작용이 별로 나타나지 않지만, 과음시에는 아세트알데히드가 축적되어 구토 및 두통 등 부작용을 일으킨다. The main component of alcohol is ethanol. When ingested, it is mainly metabolized by alcohol dehydrogenase in the liver and converted to acetaldehyde.As further metabolism progresses, acetaldehyde dehydrogenase causes Decomposes into water. Usually, when the appropriate amount of drinking these enzymes work smoothly and side effects do not appear very much, but when excessive drinking, acetaldehyde accumulates, causing side effects such as vomiting and headache.
애주가들은 음주 후의 후유증을 걱정하고 피하기 위해 여러가지 음료, 약품을 복용하기도 하지만 근본적인 숙취해소에는 미흡한 점이 많다. Lovers take various drinks and medicines to avoid and worry about the aftereffects of drinking, but they do not have enough to relieve the hangover.
그 동안 개발된 많은 숙취해소제들은 주로 혈중 알코올 농도만을 감소시키는데 목적을 두었기 때문에 과음시 부작용을 일으키는 주된 물질인 아세트알데히드에 의한 숙취를 효과적으로 완하시키고 해소시킬 수 있는 제제의 개발은 아직까지 미미한 상태이다. 이에 본 발명자들은 마그네슘화합물 및/또는 마그네슘염과 단삼추출물을 포함하는 조성물이 혈중 아세트알데히드 및 알코올 농도를 동시에 감소시킬 뿐만 아니라, 간세포 및 위벽세포 보호작용이 있음을 확인하여 본 발명을 완성하게 되었다.
Many of the hangovers developed in the past have been aimed at reducing blood alcohol levels only. Therefore, the development of drugs that can effectively alleviate and resolve hangovers caused by acetaldehyde, a major substance causing excessive side effects, has yet to be developed. to be. Accordingly, the present inventors have completed the present invention by confirming that the composition including magnesium compound and / or magnesium salt and salvia extract reduces blood acetaldehyde and alcohol concentration simultaneously, as well as hepatocellular and gastric parietal cell protection.
본 발명은 알코올 및 아세트알데히드 대사를 촉진하고 간세포 및 위벽세포를 보호하여, 알코올의 부작용을 최소화시킬 수 있는 숙취의 예방 및 해소용 조성물 및 복용시 숙취를 최소화 하는 우수한 효과를 갖는 기능성 주류를 제공하는 것을 목적으로 한다.
The present invention promotes alcohol and acetaldehyde metabolism and protects hepatocytes and gastric parietal cells, thereby providing a composition for the prevention and resolution of hangover that can minimize the side effects of alcohol and a functional liquor having an excellent effect of minimizing hangover when taken. For the purpose of
본 발명은 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분과 단삼추출물을 포함하는 숙취의 예방 및 해소용 조성물, 및 기능성 주류에 관한 것이다. The present invention relates to a composition for preventing and eliminating hangovers, and functional liquor comprising one or more components selected from the group consisting of magnesium compounds and magnesium salts and salvia extract.
본 발명의 숙취의 예방 및 해소용 조성물, 및 기능성 주류는 비타민 B1, 메치오닌, L-alanine 및 헛개나무열매추출물로 이루어진 군에서 선택된 하나이상의 성분을 더 포함할 수 있다.The composition for preventing and eliminating hangover of the present invention, and the functional liquor may further include one or more components selected from the group consisting of vitamin B1, methionine, L-alanine, and hawthorn fruit extract.
본 발명의 숙취의 예방 및 해소용 조성물, 및 기능성 주류에서 사용되는 마그네슘 화합물의 대표적인 예로는 산화마그네슘, 수산화마그네슘 등을 들 수 있으며; 마그네슘염의 대표적인 예로는 염화 마그네슘, 황산 마그네슘, 구연산 마그네슘, 젖산 마그네슘, 스테아릭산 마그네슘, 글루콘산 마그네슘 등을 들 수 있다. 특히, 산화마그네슘, 글루콘산 마그네슘 등은 좀 더 바람직한 효과를 나타낸다.
Representative examples of the composition for preventing and eliminating hangovers of the present invention, and magnesium compounds used in the functional liquor include magnesium oxide, magnesium hydroxide, and the like; Representative examples of magnesium salts include magnesium chloride, magnesium sulfate, magnesium citrate, magnesium lactate, magnesium stearate, magnesium gluconate and the like. In particular, magnesium oxide, magnesium gluconate, and the like exhibit more favorable effects.
본 발명에서 숙취의 예방 및 해소용 조성물이란 이러한 용도의 약제학적 제제, 식품, 음료, 식품 첨가제 등을 포함하는 개념이다.In the present invention, the composition for preventing and eliminating hangover is a concept including a pharmaceutical formulation, food, beverage, food additives and the like for such use.
본 발명의 숙취의 예방 및 해소용 조성물은 조성물에 포함된 마그네슘화합물 및/또는 마그네슘염을 마그네슘 함량으로 환산한 것을 기준으로 통상 1일 1-3회, 1-2400 mg/1회로 투여될 수 있으며, 바람직하게는 10-1000 mg/1회로 투여될 수 있다. The composition for preventing and eliminating hangover of the present invention can be administered 1-3 times a day, 1-2400 mg / 1 times based on the magnesium compound and / or magnesium salt contained in the composition in terms of magnesium content Preferably, 10-1000 mg / 1.
본 발명의 숙취의 예방 및 해소용 조성물은 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분을 마그네슘 함량으로 환산하여 0.01-95 중량%로 포함하고 단삼추출물을 0.001-80중량%로 포함할 수 있다.The composition for preventing and eliminating hangover of the present invention may include 0.01-95% by weight of one or more components selected from the group consisting of magnesium compounds and magnesium salts and 0.001-80% by weight of salvia extract have.
또한, 비타민 B1, 메치오닌, L-alanine 및 헛개나무열매추출물로 이루어진 군에서 선택된 하나이상의 성분을 더 포함하는 경우에는 0.001-80 중량%로 포함할 수 있다. In addition , if the vitamin B1, methionine, L-alanine, and the barberry fruit extract further comprises one or more components selected from the group may be included in 0.001-80% by weight.
알코올을 과도하게 섭취하면 위장장애를 일으킬 뿐만 아니라(Mach, T. Protective effect of alkalies on ethyl alcohol-damaged gastric mucosa. Folia Med. Cracov. 30(3-4):93-101,1989), 생체내 마그네슘의 배설을 촉진하여 혈중 마그네슘 농도를 감소시켜 심혈관계 질환(Chakraborti et al. Protective role of magnesium in cardiovascula diseases: a review. Mol Cell Biochem. Sep;238(1-2):163-79, 2002), 신장질환(Vamvakas et al. Acohl abuse: potential role in electrolyte disturbances and kidney diseases. Clin Nephrol. Apr:49(4)205-13, 1998) 및 신경계질환(Thomson. Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome. Alcohol Alchol. 2000) 등 다양한 질환을 일으키는 것으로 알려져 있다. Excessive alcohol consumption not only causes gastrointestinal disorders (Mach, T. Protective effect of alkalies on ethyl alcohol-damaged gastric mucosa.Folia Med. Cracov. 30 (3-4): 93-101,1989) Cardiovascular disease by promoting the excretion of magnesium, reducing the concentration of magnesium in the blood (Chakraborti et al. Protective role of magnesium in cardiova scula diseases: a review.Mol Cell Biochem. Sep; 238 (1-2): 163-79, 2002) (Vamvakas et al. Acohl abuse: potential role in electrolyte disturbances and kidney diseases.Clin Nephrol. Apr: 49 (4) 205-13, 1998) and nervous system diseases (Thomson. Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome.Alcohol Alchol. 2000).
본발명자들은 알코올의 섭취 전후에 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분을 적당량 섭취하면, 생체내 알코올 대사에 관여하는 알코올 디히드로게나제, 아세트알데히드 디히드로게나제 등의 효소활성을 촉진하고(Thomasson et al. Alcohol and aldehyde dehydrogenase polymorphisms and alcoholism. Behavior Genetics. 23(2):131-136, 1993), 알코올에 의한 혈중 마그네슘의 손실을 보충하는 효과가 있어서 숙취의 예방 및 해소에 효과가 있음을 발견하였다. The present inventors, by ingesting an appropriate amount of one or more components selected from the group consisting of magnesium compounds and magnesium salts before and after ingestion of alcohol, may induce enzyme activities such as alcohol dehydrogenase and acetaldehyde dehydrogenase, which are involved in alcohol metabolism in vivo. (Thomasson et al. Alcohol and aldehyde dehydrogenase polymorphisms and alcoholism.Behavioral Genetics. 23 (2): 131-136, 1993) and supplement the loss of blood magnesium by alcohol, which is effective in preventing and eliminating hangovers. Was found.
더나아가서, 알코올의 섭취 전후에 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분과 단삼추출물을 함께 섭취하면 이들 성 분의 시너지 효과에 의해서 마그네슘류만을 단독으로 섭취했을 때 보다 매우 우수한 숙취의 예방 및 해소효과가 나타남을 실험을 통하여 확인하였다.
Furthermore, by ingesting at least one ingredient selected from the group consisting of magnesium compounds and magnesium salts before and after the alcohol intake and the salvia extract, the synergy of these ingredients prevents the better hangover than when magnesium alone is ingested. And it was confirmed through experiments that the effect of resolving.
본 발명에서 사용된 단삼(Salviae miltiorrhizae Bunge)은 다년생 본초인 단삼의 뿌리로써 맛은 쓰며, 약간 찬 성질이 있는 무독성인 약재로 알려져 있으며, 단삼의 성분은 단시오닌(tanshionine), 밀티오논(miltionone), 살비아노릭산(salvianolic acid) 등이 밝혀졌고, 약리작용으로는 뇌허혈보호작용, 항고혈압작용, cisplatin에 의해 유도된 급성신장장애의 보호작용, 간섬유화 억제작용, IgE에 의한 알러지 억제작용, 암세포증식 억제작용 등이 보고되었다. Salviae used in the present invention ( Salviae miltiorrhizae Bunge) is the root of the perennial herb, the taste is bitter, known as a non-toxic medicine with a slightly cold nature, the components of the dansam is tanshionine (tanshionine), millionone ( miltionone), salvianolic acid, etc., and pharmacological actions include cerebral ischemic action, antihypertensive action, cisplatin-induced acute renal impairment, hepatic fibrosis inhibitory action, and allergy suppression effect by IgE. , Cancer cell proliferation inhibitory effect has been reported.
본 발명에 추가하여 첨가될 수 있는 메치오닌은 체내에서 활성형인 아데노실메치오닌(adenosylmethionine)으로 변화되어 레시친(lecithin)의 구성성분인 코린(choline)을 합성할 수 있도록 코린에 메칠(methyl)기를 도입시켜주는 것을 도와준다. 이로써 메치오닌은 지방간을 억제하는 간 보호효과가 있다. 또한, L-alanine은 NAD의 재생을 촉진시켜 알코올디하이드로게나제를 활성화시킴으로 알코올의 분해를 증가시킨다. 헛개나무는 지구자나무, 호깨나무 또는 허래깨나무라고도 하며 술을 지나치게 마셔서 중독된 것을 치료하는 데 헛개나무를 달여서 복용한다는 내용은 성혜방 및 진남본초 등 옛 의학서적에 많이 소개되어 있다. 헛개나무는 알코올 분해 효과가 탁월하여 쥐에 투여하면 알코올 농도를 4시간 후에 50% 이상 감소시키며, 간 보호효과가 있음이 보고되었다.
In addition to the present invention, methionine can be added to the active adenosylmethionine (adenosylmethionine) in the body by introducing a methyl group to the choline (methyl) to synthesize the choline (choline) component of lecithin Help to give As a result, methionine has a liver protective effect of inhibiting fatty liver. In addition, L-alanine promotes the regeneration of NAD and activates alcohol dehydrogenase, thereby increasing the decomposition of alcohol. The barn tree is also known as earth tree, sesame tree or barberry. The use of the barn tree in the treatment of addiction by drinking too much alcohol is introduced in old medical books such as Seonghyebang and Jinnam Herb. It has been reported that the bark tree has an excellent alcohol degrading effect, and when administered to rats, alcohol concentration is reduced by 50% or more after 4 hours, and has a liver protection effect.
본 발명의 숙취의 예방 및 해소용 조성물 중에서 이러한 용도의 약제학적 제제는 약제학적으로 허용가능한 담체, 부형제 및/또는 첨가제를 포함하는 경우에 다양한 형태로 제제화될 수 있다. 즉, 본 발명에 따른 조성물은 통상의 정제, 캅셀제, 액제, 산제 등의 경구제형, 주사제, 경피투여제제 등의 비경구 제형의 형태로 제제화될 수 있다. In the compositions for the prevention and resolution of hangovers of the present invention, pharmaceutical preparations for this use can be formulated in a variety of forms when they include pharmaceutically acceptable carriers, excipients and / or additives. That is, the composition according to the present invention can be formulated in the form of parenteral formulations such as oral formulations, injections, transdermal administrations, etc., such as conventional tablets, capsules, solutions, powders.
본 발명의 숙취의 예방 및 해소용 조성물 중에서 이러한 용도의 식품 조성물은 다양한 식품류에 적용될 수 있다. 예컨데, 음료, 차, 국, 건강보조 식품류 등을 들 수 있다.In the composition for preventing and eliminating hangover of the present invention, the food composition for this use can be applied to various foods. For example, drinks, tea, soups, health supplements and the like.
또한, 본 발명의 숙취의 예방 및 해소용 조성물은 이러한 용도의 식품 첨가제 형태로도 이용될 수 있다. 예컨데, 본 발명의 조성물을 첨가제 형태로 제조하여 각종 식품에 첨가하여 이용할 수 있다.
In addition, the composition for preventing and eliminating hangover of the present invention can also be used in the form of food additives for this purpose. For example, the composition of the present invention may be prepared in an additive form and added to various foods.
본 발명에 있어서, 또 하나의 용도인 기능성 주류 조성물은 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택되는 하나 이상의 성분을 마그네슘 함량으로 환산하여 0.01-100 g/L로 포함하고 단삼추출물을 0.001-100 g/L로 포함할 수 있다. 이러한 함량은 주류의 알코올 농도에 따라 적절히 조절될 수 있다.In the present invention, the functional liquor composition, which is another use, includes 0.01-100 g / L in terms of magnesium content of one or more components selected from the group consisting of magnesium compounds and magnesium salts and 0.001-100 g of salvia extract. Can be included with / L. This content can be appropriately adjusted according to the alcohol concentration of the liquor.
또한, 비타민 B1, 메치오닌, L-alanine 및 헛개나무열매추출물로 이루어진 군에서 선택된 하나이상의 성분을 더 포함하는 경우에는 0.001-100 g/L 중량%로 포함할 수 있다. In addition , in the case of further comprising at least one component selected from the group consisting of vitamin B1, methionine, L-alanine and hollyhock extract 0.001-100 g / L wt%.
상기에서 기능성 주류란 음주 후에 발생하는 숙취를 최소화한 주류를 의미한 다. Functional liquor in the above means a liquor with a minimum hangover that occurs after drinking.
이하에서는 본 발명을 실시예 및 실험예를 통하여 설명하고자 한다. 그러나 본 발명의 내용이 다음 실험예 한정되는 것은 아니다.
Hereinafter, the present invention will be described through Examples and Experimental Examples. However, the content of the present invention is not limited to the following experimental examples.
실시예 1 : 단삼 추출물의 제조Example 1 Preparation of Salvia Extract
단삼 1kg 70% 에탄올 3L로 50℃에서 24시간 추출하였다. 추출물을 여과하고, 잔재 생약을 다시 70% 에탄올 3L로 3회 반복하여 추출한 후, 추출액을 혼합하였다. 감압농축한 후 동결건조하여 단삼추출물 216 g을 얻었다.
1 kg 70% ethanol 3L ethanol was extracted for 24 hours at 50 ℃. The extract was filtered, and the residual crude was extracted three times with 3 L of 70% ethanol again, and the extract was mixed. Concentrated under reduced pressure and lyophilized to obtain 216 g of Salvia extract.
실시예 2 : 기능성 주류의 제조Example 2 Preparation of Functional Liquor
글루콘산 마그네슘 60 g과 단삼추출물 6g을 멸균된 증류수 1,000 ml에 용해한 후 40% 에탄올과 1:1의 비율로 혼합하여 20%(v/v) 에탄올을 제조하였다.
60 g of magnesium gluconate and 6 g of salvia extract were dissolved in 1,000 ml of sterilized distilled water, and then mixed with 40% ethanol at a ratio of 1: 1 to prepare 20% (v / v) ethanol.
실험예 1: 마그네슘 화합물 및/또는 마그네슘염과 단삼추출물의 조성물이 혈중 알콜 및 아세트 알데하이드 농도에 미치는 영향 Experimental Example 1: Effect of Magnesium Compound and / or Magnesium Salt and Salmon Extract on Composition of Blood Alcohol and Acetaldehyde
(1) 실험방법(1) Experimental method
체중 200-250g의 수컷 흰쥐(Sprague-Dawley) 6마리를 각 한 군으로 나누어 실험에 사용하였다. 동물실험군은 대조군으로서 알코올 투여군, 마그네슘 화합물 및/또는 마그네슘염을 첨가한 알코올 투여군, 단삼추출물을 첨가한 알코올 투여군, 마그네슘 화합물 및/또는 마그네슘염과 단삼추출물을 혼합하여 첨가한 알코올 투여군 및 동일한 용도로 판매되고 있는 제품(RU-21) 투여군으로 구성되었다. Six male rats (Sprague-Dawley) weighing 200-250 g were divided into one group and used for the experiment. As the control group, the animal test group was the alcohol-administered group, the alcohol-administered group with magnesium compound and / or magnesium salt, the alcohol-administered group with salviae extract, the alcohol-administered group with mixed magnesium compound and / or magnesium salt and salviae extract and the same use. It consisted of the product (RU-21) administration group on sale.
알코올 투여군에는 40% 에탄올을 2g/kg으로 경구투여하였으며;The alcohol group was orally administered with 40% ethanol at 2 g / kg;
마그네슘 화합물 및/또는 마그네슘염을 첨가한 알코올 투여군은 다음의 용량을(산화마그네슘 2, 5, 10 mg/kg; 글루콘산 마그네슘 20 mg/kg; 산화마그네슘 10 mg/kg 및 글루콘산마그네슘 10 mg/kg의 혼합) 각각 40% 에탄올에 혼합하여 경구투여하였으며,The alcohol-administered group to which the magnesium compound and / or magnesium salt was added may have the following doses (
단삼추출물을 첨가한 알코올 투여군은 단삼추출물 2 mg/kg을 40% 에탄올에 혼합하여 경구투여하였으며,In the alcohol-administered group to which salvia extract was added, 2 mg / kg of salvia extract was mixed orally administered with 40% ethanol,
마그네슘 화합물 및/또는 마그네슘염과 단삼추출물을 혼합하여 첨가한 알코올 투여군은 다음의 용량을(산화마그네슘 2 mg/kg + 단삼추출물 2 mg/kg, 산화마그네슘 5mg/kg + 단삼추출물 2 mg/kg, 산화마그네슘 10 mg/kg + 단삼추출물 2 mg/kg) 각각 40% 에탄올에 혼합하여 경구투여하였으며, 그리고The alcohol-administered group in which the magnesium compound and / or the magnesium salt and the salviae extract were mixed was added to the following doses (
동일한 용도로 판매되고 있는 제품(RU-21)은 20 mg/kg을 40% 에탄올에 혼합하여 경구투여하였다.The product sold for the same purpose (RU-21) was orally administered with 20 mg / kg mixed in 40% ethanol.
투여 후 2시간 후에 CO2 가스로 질식시킨 다음, 혈액을 채취하여 혈중 알콜 및 아세트알데히드 농도를 측정하였다.After 2 hours after administration, suffocated with CO 2 gas, blood was collected to measure blood alcohol and acetaldehyde concentration.
혈중 알콜 농도의 측정은 기체크로마토그라피로 측정하였으며, 아세트알데히드 측정은 HPLC를 아용하여 측정하였다. 혈중 아세트알데히드 농도 측정은 혈액 1ml에 3.6M HCl에 용해시킨 0.01M 디니트로페닐히드라진(dinitrophenylhydrazine, DNPH) 1ml를 첨가하여 30분 동안 실온에서 잘 혼합한 후 20 ml 펜탄(pentane)을 첨가하여 혼합한 다음 3,500rpm에서 20분간 원심분리하였다. 펜탄층을 10ml 증류수로 3회 세척한 다음 원심분리하고 펜탄층에 무수황산나트륨(Na2SO4 anhydrous)을 약간 넣어 혼합한 후 원심분리하여 펜탄층을 분리하여 증발기(evaporator)로 농축하였다. 0.5ml 아세토니트릴(acetonitrile)과 증류수를 1:1로 혼합한 용매로 HPLC로 정량하였다. HPLC의 컬럼은 Novapak C18(Waters Co.)을 사용하였으며, 전개용매는 아세토니트릴과 증류수를 1:1로 혼합하여 사용하였다. 아세트알데히드의 체류시간(retention time)은 4.95분 이었다.
Blood alcohol concentration was measured by gas chromatography, and acetaldehyde was measured by HPLC. Blood acetaldehyde concentration was measured by adding 1 ml of 0.01 M dinitrophenylhydrazine (DNPH) dissolved in 3.6 M HCl to 1 ml of blood, mixing at room temperature for 30 minutes, and then adding 20 ml pentane. Then centrifuged for 20 minutes at 3,500rpm. The pentane layer was washed three times with 10 ml of distilled water, followed by centrifugation and mixed with a small amount of anhydrous sodium sulfate (Na 2 SO 4 anhydrous) in the pentane layer, followed by centrifugation to separate the pentane layer and concentrated by an evaporator. 0.5 ml of acetonitrile and distilled water were quantified by HPLC with a solvent mixed 1: 1. HPLC column was used Novapak C18 (Waters Co.), the developing solvent was a mixture of acetonitrile and distilled water in a 1: 1. The retention time of acetaldehyde was 4.95 minutes.
(2) 실험결과(2) Experiment result
도 1에 나타낸 바와 같이, 실험군 중에서 산화마그네슘 10 mg/kg + 단삼추출물 2mg/kg 투여군 및 글루콘산 마그네슘 20 mg/kg 투여군에서 혈중 알코올 농도가 가장 현저히 감소되었다. 산화마그네슘 10 mg/kg + 단삼추출물 2mg/kg 투여군은 글루콘산 마그네슘 20 mg투여군과 비교하여, 효과면에서 비슷하나 제조상 총량적으로 훨씬 수월하다. 더불어, 기존의 숙취해소제로 개발된 RU-21 (20 mg/kg)투여군에서는 혈중 알콜농도가 대조군에 비해 유의한 차이가 없었다.
As shown in FIG. 1, blood alcohol concentrations of the
실험예 2: 산화마그네슘염과 단삼추출물의 조성물이 혈중 알콜 농도 및 아세트 알 데하이드 농도에 미치는 영향Experimental Example 2: Effect of the composition of magnesium oxide salt and salvia extract on blood alcohol concentration and acetaldehyde concentration
(1) 실험방법 (1) Experimental method
대조군과 산화마그네슘염 및 단삼추출물(산화마그네슘 2 mg/kg + 단삼추출물 2 mg/kg (M1), 산화마그네슘 10 mg/kg + 단삼추출물 2 mg/kg(M2))을 첨가한 알코올 투여군에 대하여만 실험을 실시하고, 투여 후 각각 1, 2, 4시간 후에 CO2 가스로 질식시킨 다음, 혈액을 채취하여 혈중 알콜 및 아세트알데히드 농도를 측정한 것을 제외하고는 실험예 1과 동일하게 실험하였다.
For the control group and the alcohol-administered group to which magnesium oxide salt and salvia extract (
(2) 실험결과(2) Experiment result
도 2에서 볼 수 있는 바와 같이, 산화마그네슘 10 mg/kg + 단삼추출물 2 mg/kg(M2)을 첨가한 알코올 투여군에서 2시간 대부터 혈중 알콜농도가 현저히 감소되었으나, 산화마그네슘 2 mg/kg + 단삼추출물 2 mg/kg(M1)을 첨가한 알코올 투여군은 대조군인 알코올 투여군에 비해 유의한 차이가 없었다. As can be seen in Figure 2, in the alcohol-administered group to which
또한, 도 3에서 볼 수 있는 바와 같이, 산화마그네슘 10 mg/kg + 단삼추출물 2 mg/kg(M2)을 첨가한 알코올 투여군에서는 1시간 대부터 혈중 아세트 알데하이드 농도가 현저히 감소되었으나, 산화마그네슘 2 mg/kg + 단삼추출물 2 mg/kg(M1)을 첨가한 알코올 투여군은 대조군인 알코올 투여군에 비해 유의한 차이가 없었다.
In addition, as shown in FIG. 3, in the alcohol-administered group to which
실험예 3. 글루콘산 마그네슘과 단삼추출물의 조성물이 혈중 알콜 농도에 미치는 영향Experimental Example 3. Effect of the composition of magnesium gluconate and salvia extract on blood alcohol concentration
(1) 실험방법 (1) Experimental method
대조군과 글루콘산 마그네슘 10 mg/kg + 단삼추출물 2 mg/kg(M)을 첨가한 알코올 투여군에 대하여만 실험을 실시하고, 투여 후 각각 1, 2, 4시간 후에 CO2 가스로 질식시킨 다음, 혈액을 채취하여 혈중 알콜 및 아세트알데히드 농도를 측정한 것을 제외하고는 실험예 1과 동일하게 실험하였다.
Only the control group and the alcohol-administered group to which 10 mg / kg magnesium gluconate + 2 mg / kg (M) of salvia extract were added to the test group were suffocated with CO 2 gas after 1, 2 and 4 hours, respectively. Blood was collected and tested in the same manner as in
(2) 실험결과(2) Experiment result
도 4에서 볼 수 있는 바와 같이, 글루콘산 마그네슘 10 mg/kg + 단삼추출물 2 mg/kg(M)을 첨가한 알코올 투여군에서 1시간 대부터 혈중 알코올 농도가 현저히 감소되었다.
As can be seen in Figure 4, in the alcohol administration group to which
본 발명은 알코올 및 아세트알데히드 대사를 촉진하고 간세포 및 위벽세포를 보호하여, 알코올의 부작용을 최소화시킬 수 있는 숙취의 예방 및 해소용 조성물 및 복용시의 숙취를 최소화 하는 우수한 효과를 갖는 기능성 주류를 제공한다.
The present invention promotes alcohol and acetaldehyde metabolism and protects hepatocytes and gastric parietal cells, thereby providing a composition for preventing and eliminating hangovers that can minimize side effects of alcohol and a functional liquor having an excellent effect of minimizing hangovers when taken. do.
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040082247A KR20060033247A (en) | 2004-10-14 | 2004-10-14 | Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040082247A KR20060033247A (en) | 2004-10-14 | 2004-10-14 | Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060033247A true KR20060033247A (en) | 2006-04-19 |
Family
ID=37142392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020040082247A Ceased KR20060033247A (en) | 2004-10-14 | 2004-10-14 | Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20060033247A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102580046A (en) * | 2012-03-23 | 2012-07-18 | 南宁市品迪生物工程有限公司 | Zhuang ethnic group medical recipe for preventing alcoholism and sobering up |
-
2004
- 2004-10-14 KR KR1020040082247A patent/KR20060033247A/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102580046A (en) * | 2012-03-23 | 2012-07-18 | 南宁市品迪生物工程有限公司 | Zhuang ethnic group medical recipe for preventing alcoholism and sobering up |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002102362A1 (en) | Dietetic preparation and use of an alpha-hydroxy carboxylic acid (citric acid for the treatment of obesity | |
| JP5275251B2 (en) | Composition comprising an extract of a combined herb for preventing and treating liver disease | |
| KR100877600B1 (en) | Pharmaceutical composition for the prevention and treatment of alcoholic fatty liver and fatty hepatitis containing metadoxin and garlic oil as active ingredients | |
| KR100697056B1 (en) | Composition for the prevention and treatment of liver disease, including liquirithiinin as an active ingredient | |
| WO2014010656A1 (en) | Superior blood alcohol concentration reduction accelerating agent | |
| US5464620A (en) | Pharmaceutical composition for treating gastrointestinal disease | |
| WO2006119038A1 (en) | Compositions and methods for controlling glucose uptake | |
| JP4422685B2 (en) | Use of pinitol or cayloisitol for liver protection | |
| EP4181693B1 (en) | Nutritional supplement for use in a method of protection of the liver from the effects of the use of methotrexate as a chemotherapeutic drug, comprising dihydromyricetin, choline and one or more vitamins with antioxidant activity | |
| JP4233645B2 (en) | Lipase inhibitor | |
| KR20060033247A (en) | Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor | |
| TWI334783B (en) | Pharmaceutical composition for facilitating the reduction of blood-alcohol concentration after alcohol intake | |
| JP5422370B2 (en) | Oral liquid composition | |
| JP6835396B2 (en) | Composition for reducing blood glucose concentration, reducing blood hemoglobin A1c amount, or increasing blood HDL-cholesterol level | |
| KR20050049416A (en) | Composition for prevention and relief of alcoholic hangover, and alcoholic liquors containing magnesium compound and/or magnesium salt | |
| TWI871016B (en) | Use of magau extract for preparing a composition for improving sleep and resisting depression | |
| KR20020004193A (en) | Composition for liver protection containing inhibitors of alcohol absorption | |
| TWI732147B (en) | Extracts and compositions for inhibiting acetylcholinesterase | |
| TW202513087A (en) | Composition for enhancing or improving kidney function | |
| US20080279968A1 (en) | Composition and method for inducing lipolysis and increasing the metabolism of free fatty acids | |
| JPH1072460A (en) | Prevention of neuronal cell death, therapeutic agent for improving ischemic disease and method for producing the same | |
| HK40064821A (en) | Composition for lowering blood glucose level, reducing blood hemoglobin a1c content, or increasing blood hdl-cholesterol content | |
| KR101322721B1 (en) | Anti-obesity composition containing the Platycodon grandiflorum fraction from the Platycodon grandiflorum roots with high purity platycosides | |
| KR100846441B1 (en) | Pharmaceutical Compositions, Health Food Compositions, Cosmetic Compositions, and Panasonic X Nuclear Receptor Inhibitor Compositions Containing Sterol Derivatives | |
| JP3088111B2 (en) | Saponin-containing alcohol absorption inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20041014 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20090902 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20041014 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20110412 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20110622 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20110412 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |